Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration

J Cancer Res Clin Oncol. 2005 Aug;131(8):547-51. doi: 10.1007/s00432-005-0669-9. Epub 2005 Apr 30.

Abstract

Purpose: To investigate the effects on sensitivity to fluoropyrimidine and endothelial cell (EC) migration by transfection with thymidine phosphorylase (TP) cDNA to a hepatocellular carcinoma (HCC) cell line SMMC-7721.

Methods: SMMC-7721 was transfected with pcDNA3.1/zeo (+) with human TP cDNA. TP mRNA expression was determined by RT-PCR. Sensitivity to fluoropyrimidine was determined by 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide (MTT) assay. Induction of EC migration was detected by Boyden chamber assay.

Results: The construction of pcDNA3.1/zeo(+)-TP was verified by digestion with restriction endonuclease Apa1. When comparison was made between SMMC-7721 cell clone transfected with pcDNA3.1/zeo(+)-TP (S-TP) and control clone transfected with pcDNA3.1/zeo(+) (S-vector), we found that TP mRNA expression level was much higher in S-TP, being 2.09+/-0.16 vs 0.48+/-0.06 in S-vector (P < 0.01), sensitivity to 5'-deoxy-5-fluorouridine (5'-dFUrd, a prodrug of 5-fluorouracil) in S-TP was significantly enhanced compared with that in S-vector (IC(50); 56.81+/-9.85 micromol/l vs 162.25+/-11.03 micromol/l, P < 0.01), and the culture medium of S-TP possessed more potential to induce EC migration than that of S-vector (the number of ECs appearing on the outer surfaces of the membrane was 275+/-29 vs 122+/-35 per field, P < 0.01).

Conclusion: Sensitivity to 5'-dFUrd could be enhanced by transfection with TP cDNA for SMMC-7721 cells. However, EC migration was also promoted at the same time. Therefore, transfection with TP alone might have no potential to enhance anti-tumoral effects of fluoropyrimidine in HCC.

MeSH terms

  • Antigens, Neoplasm / analysis
  • Antimetabolites, Antineoplastic / pharmacology*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / enzymology
  • Carcinoma, Hepatocellular / pathology
  • Cell Movement / drug effects
  • DNA Topoisomerases, Type II / analysis
  • DNA, Complementary / metabolism
  • DNA-Binding Proteins / analysis
  • Disease-Free Survival
  • Floxuridine / pharmacology*
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / enzymology
  • Liver Neoplasms / pathology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Analysis
  • Thymidine Phosphorylase / genetics*
  • Transfection*

Substances

  • Antigens, Neoplasm
  • Antimetabolites, Antineoplastic
  • DNA, Complementary
  • DNA-Binding Proteins
  • Floxuridine
  • Thymidine Phosphorylase
  • DNA Topoisomerases, Type II
  • doxifluridine